Evaluation of Vildagliptin (Galvus) as add-on to Insulin in Residual beta-cell Function and Inflammatory Markers in New-onset Type 1 Diabetes Mellitus.
Phase of Trial: Phase III
Latest Information Update: 06 Mar 2017
At a glance
- Drugs Vildagliptin (Primary) ; Insulin
- Indications Type 1 diabetes mellitus
- Focus Pharmacodynamics
- 07 Jun 2017 Biomarkers information updated
- 13 May 2014 Planned end date changed from 1 Aug 2014 to 1 Mar 2017 as reported by ClinicalTrials.gov.
- 13 May 2014 Trial status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.